Role of TIM-3 in ovarian cancer: the forsaken cop or a new noble

被引：1
作者：
Chang, Xiangyu [1 ]
Miao, Jinwei [1 ]
机构：
[1] Capital Med Univ, Beijing Obstet & Gynecol Hosp, Beijing Maternal & Child Hlth Care Hosp, Dept Gynecol Oncol, Beijing, Peoples R China
来源：
FRONTIERS IN IMMUNOLOGY | 2024年 / 15卷
关键词：
TIM-3; ovarian cancer; immunity; tumor-infiltrating lymphocytes; immune microenvironment; T-CELLS; EXPRESSION; MECHANISMS; BREAST; SUBSET;
D O I：
10.3389/fimmu.2024.1407403
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
T cell immunoglobulin and mucin domain-3 (TIM-3), a crucial immune checkpoint following PD1 and CTLA4, is widely found in several immune cells. Nonetheless, its performance in recent clinical trials appears disappointing. Ovarian cancer (OC), a malignant tumor with a high mortality rate in gynecology, faces significant hurdles in immunotherapy. The broad presence of TIM-3 offers a new opportunity for immunotherapy in OC. This study reviews the role of TIM-3 in OC and assesses its potential as a target for immunotherapy. The regulatory effects of TIM-3 on the immune microenvironment in OC are discussed, with a focus on preclinical studies that demonstrate TIM-3's modulation of various immune cells in OC. Additionally, the potential therapeutic advantages and challenges of targeting TIM-3 in OC are examined.
引用
收藏
页数：8
相关论文
共 78 条
  • [1] The inhibitory receptors PD1, Tim3, and A2aR are highly expressed during mesoCAR T cell manufacturing in advanced human epithelial ovarian cancer
    Akbari, Behnia
    Soltantoyeh, Tahereh
    Shahosseini, Zahra
    Yarandi, Fariba
    Hadjati, Jamshid
    Mirzaei, Hamid Reza
    [J]. CANCER CELL INTERNATIONAL, 2023, 23 (01)
  • [2] Recent Advances in Ovarian Cancer: Therapeutic Strategies, Potential Biomarkers, and Technological Improvements
    Akter, Salima
    Rahman, Md. Ataur
    Hasan, Mohammad Nazmul
    Akhter, Hajara
    Noor, Priya
    Islam, Rokibul
    Shin, Yoonhwa
    Rahman, MD. Hasanur
    Gazi, Md. Shamim
    Huda, Md Nazmul
    Nam, Nguyen Minh
    Chung, Jinwook
    Han, Sunhee
    Kim, Bonglee
    Kang, Insug
    Ha, Joohun
    Choe, Wonchae
    Choi, Tae Gyu
    Kim, Sung Soo
    [J]. CELLS, 2022, 11 (04)
  • [3] TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory
    Ausejo-Mauleon, Iker
    Labiano, Sara
    de la Nava, Daniel
    Laspidea, Virginia
    Zalacain, Marta
    Marrodan, Lucia
    Garcia-Moure, Marc
    Gonzalez-Huarriz, Marisol
    Hervas-Corpion, Irati
    Dhandapani, Laasya
    Vicent, Silvestre
    Collantes, Maria
    Penuelas, Ivan
    Becher, Oren J.
    Filbin, Mariella G.
    Jiang, Li
    Labelle, Jenna
    de Biagi-Junior, Carlos A. O.
    Nazarian, Javad
    Laternser, Sandra
    Phoenix, Timothy N.
    van der Lugt, Jasper
    Kranendonk, Mariette
    Hoogendijk, Raoull
    Mueller, Sabine
    De Andrea, Carlos
    Anderson, Ana C.
    Guruceaga, Elizabeth
    Koschmann, Carl
    Yadav, Viveka Nand
    Perez-Larraya, Jaime Gallego
    Patino-Garcia, Ana
    Pastor, Fernando
    Alonso, Marta M.
    [J]. CANCER CELL, 2023, 41 (11) : 1911 - +
  • [4] T Cell Exhaustion
    Baessler, Andrew
    Vignali, Dario A. A.
    [J]. ANNUAL REVIEW OF IMMUNOLOGY, 2024, 42 : 179 - 206
  • [5] Besse B., 2023, ESMO, DOI [10.1016/j.annonc.2023.09.2347, DOI 10.1016/J.ANNONC.2023.09.2347]
  • [6] Targeting the immune microenvironment in ovarian cancer therapy d mission impossible?
    Blanc-Durand, F.
    Pautier, P.
    Michels, J.
    Leary, A.
    [J]. ESMO OPEN, 2024, 9 (03)
  • [7] Intracellular Toll-like Receptors
    Blasius, Amanda L.
    Beutler, Bruce
    [J]. IMMUNITY, 2010, 32 (03) : 305 - 315
  • [8] B-cell-specific checkpoint molecules that regulate anti-tumour immunity
    Bod, Lloyd
    Kye, Yoon-Chul
    Shi, Jingwen
    Triglia, Elena Torlai
    Schnell, Alexandra
    Fessler, Johannes
    Ostrowski, Stephen M. M.
    Von-Franque, Max Y. Y.
    Kuchroo, Juhi R. R.
    Barilla, Rocky M. M.
    Zaghouani, Sarah
    Christian, Elena
    Delorey, Toni Marie
    Mohib, Kanishka
    Xiao, Sheng
    Slingerland, Nadine
    Giuliano, Christopher J. J.
    Ashenberg, Orr
    Li, Zhaorong
    Rothstein, David M. M.
    Fisher, David E. E.
    Rozenblatt-Rosen, Orit
    Sharpe, Arlene H. H.
    Quintana, Francisco J. J.
    Apetoh, Lionel
    Regev, Aviv
    Kuchroo, Vijay K. K.
    [J]. NATURE, 2023, 619 (7969) : 348 - +
  • [9] Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade
    Boland, Julia L.
    Zhou, Qin
    Martin, Madhuri
    Callahan, Margaret K.
    Konner, Jason
    O'Cearbhaill, Roisin E.
    Friedman, Claire F.
    Tew, William
    Makker, Vicky
    Grisham, Rachel N.
    Hensley, Martee L.
    Zecca, Nicholas
    Iasonos, Alexia E.
    Snyder, Alexandra
    Hyman, David M.
    Sabbatini, Paul
    Aghajanian, Carol
    Cadoo, Karen A.
    Zamarin, Dmitriy
    [J]. GYNECOLOGIC ONCOLOGY, 2019, 152 (02) : 251 - 258
  • [10] Ovarian carcinoma-infiltrating regulatory T cells were more potent suppressors of CD8+ T cell inflammation than their peripheral counterparts, a function dependent on TIM3 expression
    Bu, Meimei
    Shen, Yizhen
    Seeger, William L.
    An, Shizhi
    Qi, Rongqin
    Sanderson, Joanna A.
    Cai, Yan
    [J]. TUMOR BIOLOGY, 2016, 37 (03) : 3949 - 3956
12345678